18557458. SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT simplified abstract (Merck Sharp & Dohme LLC)

SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT

Organization Name

Merck Sharp & Dohme LLC

Inventor(s)

Kazuaki Shibata of Ibaraki (JP)

Hitomi Kondo of Ibaraki (JP)

Tomohiro Yamamoto of Ibaraki (JP)

Toshihiro Sakamoto of Ibaraki (JP)

Hiroki Asakura of Ibaraki (JP)

Kei Akemoto of Ibaraki (JP)

Risako Miura of Ibaraki (JP)

Tetsuya Sugimoto of Ibaraki (JP)

Juan Del Pozo of Brookline MA (US)

George Madalin Giambusu of Natick MA (US)

Thomas H. Graham of Somerville MA (US)

Yongxin Han of Needham MA (US)

Elisabeth T. Hennessy of Weston MA (US)

Shuhei Kawamura of Cambridge MA (US)

Michael Ryan of Brookline MA (US)

SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT - A simplified explanation of the abstract

This abstract first appeared for US patent application 18557458 titled 'SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT

• • Simplified Explanation:**

The patent application discusses compounds that can inhibit the G12C mutant of the KRAS protein, potentially useful for treating cancer.

• • Key Features and Innovation:**

- Compounds or their salts can inhibit the G12C mutant of KRAS protein. - These compounds may be used as therapeutic agents for cancer treatment. - Pharmaceutical compositions containing these compounds are disclosed. - Methods for using these compounds in cancer therapy and prophylaxis are provided.

• • Potential Applications:**

- Treatment of various types of cancer. - Development of targeted therapies for KRAS-mutant cancers. - Research in precision medicine and personalized cancer treatment.

• • Problems Solved:**

- Lack of effective treatments for KRAS-mutant cancers. - Need for targeted therapies with fewer side effects. - Challenges in developing precision medicine approaches for cancer.

• • Benefits:**

- Improved treatment options for patients with KRAS-mutant cancers. - Potential for more effective and targeted therapies. - Advancement in precision medicine and personalized cancer treatment.

• • Commercial Applications:**

Title: "Inhibitors of KRAS G12C Mutant for Cancer Therapy" This technology has potential commercial applications in: - Pharmaceutical companies developing cancer therapies. - Biotechnology firms focusing on precision medicine. - Research institutions studying targeted cancer treatments.

• • Questions about Inhibitors of KRAS G12C Mutant:**

1. How do compounds that inhibit the G12C mutant of KRAS protein work in cancer treatment? 2. What are the potential challenges in developing pharmaceutical compositions based on these compounds?

Original Abstract Submitted

Compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.